Browsing by Author "Matthanaporn Saesong"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    PublicationMetadata only
    CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and real-world evidence
    (2021-11-01) Chiraphat Kloypan; Matthanaporn Saesong; Juthamat Sangsuemoon; Prawat Chantharit; Pajaree Mongkhon; University of Phayao; Charité – Universitätsmedizin Berlin; Faculty of Medicine Ramathibodi Hospital, Mahidol University; Chiang Mai University
    Background: There is still a lack of consensus on the efficacy of convalescent plasma (CP) treatment in COVID-19 patients. We performed a systematic review and meta-analysis to investigate the efficacy of CP vs standard treatment/non-CP on clinical outcomes in COVID-19 patients. Methods: Cochrane Library, PubMed, EMBASE and ClinicalTrials.gov were searched from December 2019 to 16 July 2021, for data from clinical trials and observational studies. The primary outcome was all-cause mortality. Risk estimates were pooled using a random-effect model. Risk of bias was assessed by Cochrane Risk of Bias tool for clinical trials and Newcastle-Ottawa Scale for observational studies. Results: In total, 18 peer-reviewed clinical trials, 3 preprints and 26 observational studies met the inclusion criteria. In the meta-analysis of 18 peer-reviewed trials, CP use had a 31% reduced risk of all-cause mortality compared with standard treatment use (pooled risk ratio [RR] = 0.69, 95% confidence interval [CI]: 0.56-0.86, P =.001, I2 = 50.1%). Based on severity and region, CP treatment significantly reduced risk of all-cause mortality in patients with severe and critical disease and studies conducted in Asia, pooled RR = 0.61, 95% CI: 0.47-0.81, P =.001, I2 = 0.0%; pooled RR = 0.67, 95% CI: 0.49-0.92, P =.013, I2 = 0.0%; and pooled RR = 0.62, 95% CI: 0.48-0.80, P <.001, I2 = 20.3%, respectively. The meta-analysis of observational studies showed the similar results to the clinical trials. Conclusions: Convalescent plasma use was associated with reduced risk of all-cause mortality in severe or critical COVID-19 patients. However, the findings were limited with a moderate degree of heterogeneity. Further studies with well-designed and larger sample size are needed.